Clinical TrialApr 21, 2026, 07:02 AM
Rezolute to Present Phase 3 sunRIZE Data for Ersodetug at PES Meeting
AI Summary
Rezolute announced that results from its Phase 3 sunRIZE study of ersodetug for congenital hyperinsulinism (HI) were accepted for an oral presentation at the Pediatric Endocrine Society (PES) Annual Meeting. The presentation, scheduled for May 1, 2026, will include previously announced topline results along with new pre-specified and post-hoc data analyses. The company believes these updates will further demonstrate ersodetug's target engagement and therapeutic benefit, potentially bolstering confidence in the drug's development.
Key Highlights
- Rezolute to present Phase 3 sunRIZE study results for ersodetug in congenital HI.
- Oral presentation at Pediatric Endocrine Society (PES) Annual Meeting.
- Presentation scheduled for May 1, 2026, from 8:15 a.m. 9:15 a.m. PT.
- Includes previously announced topline results and new pre-specified/post-hoc data.
- Company believes data demonstrates therapeutic benefit of ersodetug.
Price Impact
More from RZLT